Boston Scientific Corporation (NYSE: BSX) is set to acquire SoniVie Ltd, an Israel-based medical device company known for its TIVUS intravascular ultrasound system. The TIVUS system is designed to treat hypertensive disorders, including renal artery denervation (RDN) for hypertension, by denervating nerves surrounding blood vessels. The product is expected to start the global pivotal THRIVE study soon, following positive efficacy data in recent trials.
Acquisition Details
Boston Scientific currently holds a strategic equity stake of approximately 10 percent in SoniVie. The deal, expected to close in the first half of 2025, involves Boston Scientific paying USD 360 million for the remaining 90 percent stake and up to USD 180 million upon achieving a regulatory milestone.-Fineline Info & Tech
Leave a Reply